Trial Profile

A Phase 1 Study of GEN2 in Adult Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEN 2 (Primary) ; GEN 2 (Primary) ; Valganciclovir
Indications Breast cancer; Liver cancer; Skin cancer; Solid tumours
Focus Adverse reactions
Sponsors GenVivo

Most Recent Events

13 May 2025 According to a GenVivo media release, company will present data from this study in a poster presentation at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, May 13th -17th, in New Orleans, LA.
18 Dec 2024 Planned number of patients changed from 91 to 124.
27 Jun 2024 According to a GenVivo media release, the company has dosed the first US patient in a Phase I/Ib, open-label, dose-escalation and expansion clinical trial of GEN2.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com